Valeant's stock is down around 9%, sliding on the news that investor Bill Ackman's hedge fund, Pershing Square, is unloading its entire stake in the company.
ADVERTISEMENT
And yes, Valeant's stock is getting hammered (VRX)
A day after the company's biggest cheerleader on Wall Street sold his stake, Valeant is feeling the pain
ADVERTISEMENT
This ends a three-year involvement with the company for Ackman. During that time, Valeant's stock price fell from a high of about $279 in the summer of 2015, to where it sits under $11 today.
The company became the subject of several federal investigations, including one involving a secret pharmacy that it used to operate which is now be accused of insurance fraud.
And it was pressured to hire a new CEO while its executives were repeatedly called to Washington for Congressional hearings to answer for drug price increases.
ADVERTISEMENT
It was quite a ride.
FOLLOW BUSINESS INSIDER AFRICA
ADVERTISEMENT
Recommended articles
UK sends first voluntary asylum seeker to Rwanda
FCMB Group records 186% profit growth, proposes 50k dividend
Accounting with a Purpose - Moracle Ghana CEO has simplified accounting for small businesses and nonprofits
10 African countries with the lightest debt burden in 2024
Sale of African skulls in a British museum comes to light
Coinremitter claims to be a leading crypto payment gateway in the market
African countries projected to gain the most rich people
Nigeria claims $600m Maersk deal sealed but the company seems unaware of such deal